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Abstract

CHARACTERIZATION OF CYCLIC DI-GMP BINDING BY THE SOLE BORRELIA
BURGDORFERI AND BORRELIA HERMSII PILZ DOMAIN-CONTAINING PROTEINS
By Katherine L. Mallory, M.S.
A thesis submitted in partial fulfillment of the requirements for the degree of
Master of Science at Virginia Commonwealth University
Virginia Commonwealth University, 2013
Major Director: Richard T. Marconi, Ph.D.
Professor, Department of Microbiology & Immunology

Borrelia burgdorferi and Borrelia hermsii cause Lyme disease and relapsing
fever, respectively. These spirochetes are maintained in an enzootic cycle, involving tick
vectors and mammalian hosts. Differential gene expression is central in their survival in
various environmental conditions. C-di-GMP has been demonstrated to be important in
bacterial adaptation. Borrelia deletion mutant phenotypes have shown that c-di-GMP
regulates motility, infectivity, and enzootic cycle progression. As the only known
receptors encoded by Borrelia, PlzA and PlzC characterization is necessary in
delineating c-di-GMP roles within the cell. In this study, biochemical, biophysical, and
FRET methods demonstrated that these proteins exhibit a structural rearrangement
when binding c-di-GMP likely significant to downstream activities. Substitution of a
highly conserved residue within PlzA altered the structure and charge of the PilZ

ix

domain, leading to abolished binding. PlzA and PlzC functionality studies are vital to
discover mechanisms of c-di-GMP-mediated regulation of motility and host invasion by
the Borrelia.

x

Chapter 1: Introduction

Borrelia genus
The genus Borrelia contains a group of enigmatic bacterial species which are
defined by many unique properties. Despite being Gram-negative, the Borrelia lack the
lipopolysaccharides characteristic of most Gram-negative species (134). They have
developed highly fragmented genomes, consisting of a linear chromosome and multiple
linear and circular plasmids (11, 13). In addition to fragmentation, Borrelia genomes
have severely reduced metabolic and biosynthetic genetic information, making them
highly reliant on their hosts for nutrients and basic metabolites (52, 99). These species
have a distinct spiral morphology, the architecture of which is generated by the polar
flagellar bundles (16). This spiral shape confers a very unique motility phenotype and
contributes to infectivity (74, 130). Despite and because of these unusual properties,
Borrelia species cause multiple infections across a range of mammalian, reptilian,
avian, and arthropod hosts.
Most motile bacteria have external flagella or cilia to allow for translational motion
(18). However, the Borrelia are unique in that their flagella are contained within the
periplasmic space between the outer and cytoplasmic membrane depicted in Figure 11. These flagellar bundles are comprised of seven to eleven filaments insert into the
cytoplasmic membrane at each end of the bacterium (75). These filaments form flat
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Figure 1-1. Borrelia periplasmic flagellla. The top panel is a depiction of a spirochete
with an outer and cytoplasmic membrane, between which lies the periplasmic space.
The unique, internal flagella wind around the protoplasmic cylinder, generating the
spirochete morphology. The bottom panel shows the flagellum inserted into the
cytoplasmic membrane by the flagellar motor.
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ribbons and wind around the cell cylinder to generate the characteristic shape of these
spirochetes (102). Each flagellum anchors into the cytoplasmic membrane by a motor
complex that controls the rotational motion of the flagellum (75). Each of these motors is
capable of clockwise and counter-clockwise rotation, which results in a “tumble” or “run”
motility in most bacteria (18). However, due to the internal flagellar bundles at each
pole, the Borrelia exhibit a “run,” “flex,” and “reverse” phenotype shown in Figure 1-2
(83). The “run” is when both flagellar motors are rotating in opposite directions and
results in a corkscrew-like motility. When one bundle changes flagellar rotation, a
spasming of the bacterium occurs. This is referred to as a “flex” and is a pause in
translational motion, much like a “tumble” (18, 83). When the bundles are rotating
asymmetrically once more, but in the opposite direction of the original “run,” it is a
“reverse.” This motility pattern allows spirochetes to migrate through highly viscous
environments such as connective tissue and contributes to pathogenicity (36, 68, 75,
130).
Two major branches exist within the Borrelia genus and these are defined by the
diseases that the bacteria cause. One branch encompasses the Lyme disease-causing
species, including B. afzelii, B. americana, B. andersonii, B. bavariensis, B. bissettii, B.
burgdorferi, B. californiensis, B. carolinensis, B. garinii, B. japonica, B. kurtenbachii, B.
lusitaniae, B. sinica, B. tanukii, B. turdi, B. spielmanii, B. valaisiana, and B. yangtze
(112). The other branch contains the relapsing fever spirochetes, B. hermsii, B.
turicatae, B. duttonii, B. dugesi, B. crocidurae, B. parkeri, and B. recurrentis (41, 47). All
of the listed species are tick-borne pathogens with the exception of B. recurrentis, which
is spread by the human body louse, Pediculus humanus humanus (47). The work
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Figure 1-2. Spirochete motility controlled by flagellar rotational direction. The
“run,” “flex,” and “reverse” motility of the spirochete is dependent on the rotational
direction of the polar flagellar bundles. The top image shows the “run” phenotype where
each pole is rotating in opposite directions. This allows translational motion to the right.
The image below that is with the asymmetrical rotation of the flagella in the opposite
direction of the “run” which results in a “reverse” and translation motion to the left. The
bottom two images show the bundles rotating in the same directions, which presents as
a “flex.”
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contained within this thesis is concentrated on two species of Borrelia to represent the
two branches within the genus, B. burgdorferi as a part of the Lyme disease branch and
B. hermsii of the tick-borne relapsing fever branch. Both of these species are the most
common cause of their respective diseases in North America.

Lyme disease
Lyme borreliosis is an emerging infectious disease that first made its debut in the
mid-1970s near Lyme, CT (128). The disease was associated with severe arthritis and
an expanding “bull’s eye” rash, previously described by Arvid Afzelius in 1909 (2). He
observed it in relation to the bite of a hard-bodied tick and named this lesion the
‘erythema migrans’ rash. In addition to this dermatological manifestation, patients of the
Lyme epidemic developed neurological, articular, and cardiac abnormalities (51, 85,
104, 127). These disease symptoms were associated with the bite of the Ixodes
scapularis tick and, later, with the presence of a B. burgdorferi infection (27). Soon after,
B. burgdorferi was isolated from the reservoir species, Peromyscus leucupus and the
tick-mouse transmission confirmed (17, 24, 29). Since then, Lyme disease has been
diagnosed in North America, Europe, and Asia with three major species causing the
disease. Two of these (B. garinii and B. afzelii) are only present in Europe and Asia and
spread by the Ixodes ricinus and Ixodes persulcatus ticks.

In North America, B.

burgdorferi is the primary causative agent and is spread by I. scapularis and Ixodes
pacificus (28, 30, 64, 90).
In the United States, Lyme disease is the most common vector-borne disease
and the sixth most common nationally notifiable disease (1, 34). In 2011, there were
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33,097 confirmed and probable cases according to the CDC. This makes the national
incidence rate 7.8 per 100,000 population (34). These statistics are considered to be
under-representative of actual infection numbers due to severe under-reporting and
misdiagnosis (33, 145). Additionally, 96% of the cases occurred in specific geographical
regions, the Northeast, mid-Atlantic, and upper Midwest; this is shown in Figure 1-3
(34). The reported incidence of individual states per 100,000 was as high as 84.6
(Delaware) and was 28.7 between the 14 states that are considered to be part of the
endemic regions: Connecticut, Delaware, Maine, Maryland, Massachusetts, Minnesota,
New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont,
Virginia, and Wisconsin (individual state statistics can be found in Table 1-1) (34).
Lyme disease has a wide range of signs, symptoms, and manifestations.
However, subclinical infections have been shown to occur through seroprevalence
studies done in endemic regions (49). It is important to note that the human immune
response to early infection by one strain of Lyme Borrelia is non-protective against other
strains, resulting in reinfection (59, 86, 88, 122). The “hallmark” sign of early invasion is
the erythema migrans rash, but only occurs in 60-85% of patients (85, 124). Other
symptoms of acute infection can include fatigue, myalgia, arthralgia, headache, fever,
and chills (85). However, an early diagnosis and subsequent treatment with oral
antibiotics such as doxycycline or amoxicillin has proven very effective in the treatment
of Lyme disease (125).
Due to non-specific signs of early infection, Lyme borreliosis is often allowed to
progress untreated for long periods, which can lead to more serious sequelae. Later
manifestations

can

include

Lyme

arthritis,

6

neurological

conditions

such

as

Figure 1-3. 2011 case distribution of Lyme disease in the United States. A map of
the location of confirmed cases of Lyme disease in the United States that occured in
2011. Each dot represents a single case randomly placed in the county of residence.
The endemic region of Lyme disease primarily lies in the Mid-Atlantic, Northeast, and
upper Midwest.
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Table 1-1. Case numbers and incidence rates in the United States per state.
State

Confirmed

Probable

Incidence*

Alabama

9

15

0.2

Alaska

9

2

1.2

Arizona

8

7

0.1

Arkansas

0

0

0

California

79

13

0.2

Colorado

0

0

0

Connecticut

2004

1035

56

Delaware

84.6

767

106

DC

N

N

N

Florida

78

37

0.4

Georgia

32

0

0.3

Hawaii

0

0

0

Idaho

3

1

0.2

Illinois

194

0

1.5

Indiana

81

13

1.2

Iowa

72

28

2.4

Kansas

11

6

0.4

Kentucky

3

0

0.1

Louisiana

1

1

0

801

205

60.3

Maryland

938

413

16.1

Massachusetts

1801

675

27.3

89

15

0.9

Minnesota

1185

939

22.2

Mississippi

3

2

0.1

Missouri

5

3

0.1

Montana

9

2

0.9

Nebraska

7

4

0.4

Nevada

3

2

0.1

New Hampshire

887

412

67.3

New Jersey

3398

864

38.5

New Mexico

2

4

0.1

3118

1372

16

North Carolina

18

70

0.2

North Dakota

22

5

3.2

Ohio

36

17

0.3

Oklahoma

2

0

0.1

Oregon

9

29

0.2

Pennsylvania

4739

623

37.2

Rhode Island

111

48

10.6

South Carolina

24

13

0.5

South Dakota

2

2

0.2

Tennessee

5

32

0.1

Texas

28

46

0.1

Utah

6

3

0.2

Vermont

476

147

76

Virginia

756

267

9.3
0.2

Maine

Michigan

New York

Washington

17

2

West Virginia

107

11

5.8

Wisconsin

2408

1241

42.2

Wyoming

1

1

0.2

24,364

8,733

7.8

U.S. TOTAL

*per 100,000 population

Table adapted from the 2012 CDC report
(http://www.cdc.gov/lyme/stats/chartstables/reportedcases_statelocality.html)

8

neuroborreliosis, cutaneous disorders, and cardiac abnormalities such as endocarditis
(7, 51, 60, 129, 139). Beyond the potential for debilitating medical conditions, the
financial burden of Lyme disease in the United States is severe. A study was done
calculating the approximate cost per case; this came to approximately $8200 in a 2006
study (146). Despite the substantial financial burden that Lyme disease imposes,
prevention is restricted to avoidance of exposure to high-risk environments and early
recognition of acute symptoms. As the causative agent of Lyme disease in the United
States, B. burgdorferi is a prominent pathogen with fascinating survival mechanisms in
hosts spanning multiple phyla.
B. burgdorferi is a bacterial species that must survive by efficiently transmitting
between two highly dissimilar host environments in a process known as the enzootic
cycle. As a tick-borne pathogen, the bacteria are spread by the deer tick (I. scapularis),
which has a two year life cycle depicted in Figure 1-4 (102). Eggs are laid in early spring
and hatch in the summer (102). The larval tick that emerges is uninfected since B.
burgdorferi are incapable of transovarial transmission (102). In late summer and early
fall, the larvae feed on one of a plethora of mammalian, avian, and reptilian hosts (102).
Transmission of B. burgdorferi to the tick vector often occurs at this stage by feeding on
an infected member of the small mammal reservoir, commonly the white-footed mouse
(102). The larvae then molt into the nymphal stage and lay dormant through the winter,
through this time the bacteria remain in the mid-gut (102). These nymphal ticks take
their second blood-meal in the spring or summer (102). It is this blood meal that causes
the spirochetes to migrate into the salivary glands and effectively transmit to this
secondary host, resulting in infection (73, 126). In the fall, nymphs moult into adults
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Figure 1-4. Enzootic cycle of the Lyme disease spirochete. The B. burgdorferi
vector is primarily the I. scapularis tick, which has a complex, multi-stage life cycle. The
cycle begins with eggs hatching in the summer. The larvae ticks that emerge are free of
Borrelia. In the summer and fall, the ticks feed on their first host, which range widely in
variety and include squirrels, mice, and birds. It is from this blood-meal that the ticks
often obtain the bacteria. The fed tick drops off the host and remains dormant through
the winter, moulting into the nymph life stage. The tick then feeds on a second host in the
spring or summer and this is where transmission of the Lyme spirochete occurs.
Infection of small mammal and avian hosts results in the continuity of the enzootic cycle.
Fed nymphs drop off and moult into the adult stage. Adults feed and procreate on large
mammals such as deer in the fall and winter, after which the adult females lay eggs in the
spring. These eggs are uninfected since B. burgdorferi cannot transmit to the ova of the
tick. It is significant to note that humans and canines are able to be infected, but they are
dead-end hosts and do not contribute to the perpetuation of the bacteria in the
environment. A hallmark symptom of human infection by B. burgdorferi is a “bulls-eye”
or erythema migrans rash.
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(102). It is in this stage that the ticks feed and copulate on large mammals such as deer
through the fall and spring (102). Deer are incompetent hosts for B. burgdorferi, but
facilitate the spread of the disease by traversing great distances and expanding the
range of potential hosts (102). In the spring, the enzootic cycle ends with the adult
female laying eggs and dying (102). It is significant to note that while humans and dogs
are capable of being infected, they are usually dead-end hosts and do not contribute to
the perpetuation of the bacteria in the environment.
Because B. burgdorferi must survive within two disparate host environments,
drastic transcriptional and translational changes must occur to effectively transmit and
avoid each host’s defenses (50, 121). Despite the necessity for rapid, global
transcriptional changes, the B. burgdorferi genome contains very few transcriptional
regulators. For example, only three sigma factors (RpoD, RpoN, and RpoS) have been
identified in the B. burgdorferi genome (52). RpoD (σ70) is the general, house-keeping
sigma factor. RpoN (σ54) has been shown to transcribe multiple genes including RpoS,
the other alternate sigma factor (26, 66). RpoS (σ38/ σs) aids in transcription of hostspecific factors such as OspC, an outer surface protein only expressed in early
mammalian infection (66). Synthesis of RpoS has multiple regulatory elements. Rrp2 (a
two-component response regulator) is a σ54 enhancer-binding protein that requires
phosphorylation to activate the transcription of rpoS (144). BosR is a DNA binding
protein shown to directly interact with the rpoS promoter and allow transcription (91).
Along with transcriptional regulation, RpoS synthesis is also temperature-regulated at
the translational level by a small RNA, DsrA, which is stabilized by the RNA chaperone
Hfq (76, 77).
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Regulatory elements are often suppressed or induced by environmental stimuli.
A method that bacteria use to detect those stimuli is two-component systems. Most
bacteria have many two-component regulatory systems, such as Escherichia coli with
30 to 60 (52). However, B. burgdorferi encodes five, only two of which are capable of
global regulation (84, 144). These are Rrp1-Hpk1 and Rrp2-Hpk2 (107, 144). The Rrp2Hpk2 system has been implicated in rpoS transcriptional regulation that initiates survival
mechanisms specific to the mammalian host. Response regulators often contain DNAbinding domains, including Rrp2 (144). However, Rrp1 lacks a DNA-binding domain, but
instead has a GGDEF domain and will be expounded upon later in this thesis (107,
116). As in other two-component systems, activation of the response regulator, Rrp1,
requires phosphorylation by the cytoplasmic membrane-embedded histidine kinase,
Hpk1 (32, 62, 116). In this manner, the sensory protein detects an external stimulus to
initiate downstream functions and regulate cell activity (142). The scarcity of broadspectrum regulatory pathways correlates with the overall minimization of the B.
burgdorferi genome.
Small, fragmented, and condensed, the B. burgdorferi genome is comprised of a
0.91 Mb linear chromosome as well as a cohort of linear and circular plasmids that
varies from strain to strain; the type strain B31 has 12 linear and 9 circular plasmids
(105). The collective coding sequences of the chromosome occupy 93% of the genetic
material with a great deal of gene overlap (52). This compacted chromosome expresses
most of the housekeeping genes while others, many vital to bacterial survival in hosts,
are expressed off of the bacterium’s arsenal of plasmids (e.g. OspC from cp26, 102).
Despite its genetic dwarfism, B. burgdorferi has retained 54 chemotactic/motility genes;
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this correlates with approximately 6% of the genome (52). This large percentage and
the fact that non-motile B. burgdorferi are non-infectious exemplify the importance of
motility for B. burgdorferi survival (74).

Tick-borne relapsing fever
Unlike the more recently discovered Lyme disease, relapsing fever has far more
ancient roots in human history. Since the days of Hippocrates, a disease was described
similar to what is known as relapsing fever today (41). Louse-borne relapsing fever
(caused by B. recurrentis) is likely correlated with the yellow plague of Europe in 550
A.D. and was responsible for millions of cases during World War I and II (111). Tickborne relapsing fever (TBRF) occurs throughout the world with the highest incidence
rates in Africa (47). Unfortunately, most African countries do not have a reporting
system for TBRF, so the actual infection rates of this disease are difficult to discern (78).
However, infection studies in smaller populations have been conducted and provide
insight into the severity of impact that TBRF can have.
The soft-bodied Ornithodoros tick is the vector for TBRF. Unlike the Lyme
disease species, the TBRF spirochetes can use their vector as a reservoir species due
to transovarial transmission and long-term survival (47, 123). Ornithodoros ticks live in
protected niches of caves, mud-huts, trees, and cabins where small mammals frequent
(118). Unlike the Ixodes, Ornithodoros ticks can live for many years and adult females
reproduce after every blood-meal of that lifespan (8, 47, 79). Because of the life cycle
and span of its tick vector, there are high percentages of TBRF-infected ticks in the
environment (8, 41, 118).
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Like Lyme disease, the endemic regions of TBRF are highly specific to the
habitat and distribution of the vector species (93). For example, in the United States,
50% of TBRF cases have occurred in only 13 counties and this distribution is shown in
Figure 1-5 (47). This endemic region correlates with the presence of the most common
cause, B. hermsii and its vector, O. hermsi (45).
Another factor in TBRF epidemiology is the living conditions of the human
population. For example, many African communities live in mud-huts, which are an ideal
location for ticks to reside and feed on the human inhabitants at night (43, 92). Studies
in Senegal revealed TBRF as the most common bacterial infection and the Tanzanian
town of Mvumi reported TBRF to be the 7th highest cause of death in children with a
perinatal mortality rate of 436 per 1000 cases (42, 78, 136, 140). While cases in the
United States are generally unsuspecting cabin vacationers, TBRF is a global health
concern with severe medical outcomes.
Disease progression of TBRF begins with exposure to the bacteria through a
tick’s blood-meal that can last from a fifteen minutes to two hours (47, 79, 92). These
blood-meals are brief, nocturnal, and painless, primarily occurring while the human host
is asleep (47, 140). The transmission of the bacteria from the tick vector to the
mammalian host is rapid and may take as little as 30 seconds, while B. burgdorferi
transmission requires 24 to 48 hours (47). After infection, there is an incubation period
that lasts for several days before disease signs and symptoms begin (47).These are
variable and can include headache, myalgia, nausea, arthralgia, and/or abdominal
complaints (47). Some less transient

manifestations include neuroborreliosis,

splenomegaly, and myocarditis (4, 31, 141). However, the most common and name-

14

Figure 1-5. Tick-borne relapsing fever incidence in the United States. Above is the
distribution of TBRF cases in North America. Highlighted are the counties in which
TBRF patients had been diagnosed up to 2002.
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sake symptom is a recurring, severe fever, often near or surpassing 104oF (45, 123).
These febrile periods correlate with high levels of blood spirochetemia (47, 92). The first
febrile period lasts an average of three days with approximately a week between the
end of the initial febrile period and the start of the first relapse (47). As many as 13
relapses have been documented with spirochetemia reaching from 10 6 to 108 bacteria
per mL of blood (42, 45). This clinical outcome is due to afebrile period sequestration of
the bacteria in the internal organs and then reemergence resulting in the fever symptom
(93). The molecular mechanism by which B. hermsii causes this recurring fever is
through antigenic variation (14).
B. hermsii has been shown to have as many as 40 different serotypes that can
be generated from a single spirochete (105). This is possible through several
mechanisms of genetic recombination that result in one of many silent variable major
protein (vmp) genes translocating to the downstream region of the appropriate
promoter, allowing transcription (12, 106). It is with the expression of a new Vmp that
the dominant serotype of the B. hermsii population changes, leading to immune evasion
and increased spirochetemia (105).
Antigenic variation and other elaborate mammalian host-specific immune evasion
mechanisms are often associated with efficient signal transduction systems to alter the
B. hermsii transcriptome upon host invasion. While this species is not quite as
dependent on its mammalian host for survival as the Lyme disease spirochetes, B.
hermsii regularly infects small mammals such as tree squirrels, chipmunks, and ground
squirrels (46). Therefore, this species must also harbor mechanisms of global
transcriptional regulation specific to the tick-mammal and mammal-tick transmission.
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Cyclic di-GMP
Borrelia undergo rapid, drastic changes in gene expression and biochemical
processes that require efficient signal transduction systems. Bis-(3'-5')-cyclic dimeric
guanosine monophosphate (c-di-GMP) is a recently discovered bacterial secondary
signaling molecule originally shown to regulate cellulose synthesis in Gluconacetobacter
xylinus (110). Since then, it has been implicated in the regulation of many pathways
among a plethora of bacterial species (5, 9, 67, 116).
All second messenger molecules function to relay signals, altering downstream
cellular processes. These messengers are often small, making them energy efficient
and capable of rapid diffusion throughout the cytoplasm. Structurally, c-di-GMP
comprises two GMP molecules connected by two phosphodiester linkages and is
depicted in Figure 1-6. These linkages result in a rigid, twelve-member ring, but
flexibility in the glycosidic bonds between the ribose sugars and guanine bases allows
for c-di-GMP to exist in two primary conformations (53, 117). The open conformation is
depicted in Figure 1-7a, and the closed in Figure 1-7b. This difference in the glycosyl
torsion angle is seen in other cyclic di-nucleotides, such as cyclic dimeric adenosine
monophosphate (53). It is also significant to note that two monomers of c-di-GMP in the
closed conformation are capable of associating due to base pair stacking. This results in
an intercalated dimer, shown in Figure 1-7b (20, 48). C-di-GMP is capable of higher
orders of oligomerization although it primarily exists in the monomer or dimer form at
physiologically relevant concentrations (48, 117).
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Figure 1-6. Cyclic di-GMP structure. Two GTP molecules are circularized by a
diguanylate cyclase to form c-di-GMP. Two phosphodiester bonds generate a twelve
member ring out of the ribose sugars and phosphate groups.
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Figure 1-7. Cyclic di-GMP conformations allow for multimerization. The flexibility
of the glycosidic bond between the ribose sugar and the guanine base allows for two
primary conformations. The open conformation is shown in panel A while the closed
conformation can be seen in panel B. In the closed conformation, two c-di-GMP
molecules can also intercalate through base pair stacking of the guanines as well as
hydrogen bond formation between the phosphate group of one molecule and the
guanine base of the other.
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Synthesis of c-di-GMP from two guanosine triphosphate (GTP) molecules is
carried out by a group of proteins known as diguanylate cyclases (DGCs), which are
typified by a GGDEF protein domain (9, 35, 63, 96, 135). It is at a conserved loopforming motif (formed by the GGDEF sequence) where binding of the two GTPs occurs
at a dimeric interface between two domains (95, 97). The GGDEF motif associates with
one molecule of GTP by interacting with the phosphates as well as the guanine base
and contributes to the high degree of binding specificity of these proteins (35).
Breakdown is carried out by phosphodiesterases (PDEs), of which there are two
groups. Some contain an EAL motif and these hydrolyze only one of the phosphodiester
bonds of c-di-GMP, forming a pGpG molecule (21). Others contain an HD-GYP domain
and catabolize c-di-GMP into its two GMP constituents (38, 57, 58, 114). It is through
the activity of DGCs and PDEs that c-di-GMP levels and downstream effects are
modulated within the cell.
C-di-GMP signaling regulates a variety of cellular functions among many
bacterial species. As a matter of fact, c-di-GMP-metabolizing proteins have been
discovered in most major phyla (109). The first discovered function of c-di-GMP was
activation of exopolysaccharide biosynthesis in the form of cellulose production in G.
xylinus (110). This has since expanded to include others, such as alginate production in
Pseudomonas aeruginosa (81, 82). Other common regulatory functions of c-di-GMP
include cell cycle progression, virulence factor production, and long-term persistence
(23, 72, 80, 96, 138). However, perhaps the most defined functions of c-di-GMP are
biofilm formation and motility (82). As a bacterial process known to confer properties
that increase pathogenicity, biofilm formation has been a major area of focus in c-di-
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GMP research (108). Among multiple species, including prominent pathogens such as
Yersinia pestis, Vibrio cholerae, Salmonella enterica, and P. aeruginosa, increased
levels of c-di-GMP induce biofilm formation while decreased levels result in an increase
in planktonic cells and motility (22, 23, 40, 120, 137). These phenotypes are exhibited
through c-di-GMP-induced regulation of gene expression and protein activity (37, 115,
143).
Cellular functions modulated by c-di-GMP can be altered at multiple stages within
the biochemical pathways, including transcription, translation, and post-translational
modifications (109). The transcription of messenger ribonucleic acid (mRNA) can be
regulated by binding of transcription factors, enhancers, or suppressors (109). In this
way, gene expression may be upregulated or downregulated depending on intracellular
c-di-GMP levels (109). Once the target genes are transcribed, translational regulation
can be carried out by c-di-GMP-activated proteins or riboswitches, which are secondary
structures within mRNA that can directly bind c-di-GMP to promote or inhibit translation
(109). Lastly, c-di-GMP can regulate protein levels and functionality through proteolysis,
activation, or deactivation (44).
C-di-GMP-mediated regulation is highly reliant on the receptors/effectors to
which this second messenger binds. Known receptors come in many forms and carry
out an array of functions. Two types of riboswitches have been discovered to bind c-diGMP and are present in many species, often with multiple incidences within a single
genome (109). Other receptors can include degenerative GGDEF, EAL, or HD-GYP
domain proteins that have lost their catalytic activity, but are still capable of binding c-diGMP (109). The last group of common receptors contains a highly conserved domain
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known as the PilZ domain (6). This domain confers c-di-GMP binding with a moderate
to high affinity (6). Other receptors are less predictable and therefore difficult to find, but
are gradually being discovered.
The PilZ domain was first discovered by bioinformatics analyses and postulated to
bind c-di-GMP, which was quickly confirmed experimentally and named after the P.
aeruginosa PilZ protein (3, 6, 115). These studies and more have shown that several
residues are highly conserved and these form an RxxxR/DzSxxG motif where x
represents any amino acid and z represents a hydrophobic amino acid. Crystallography
and nuclear magnetic resonance studies have shown that these residues do, indeed,
interact with c-di-GMP and that it can be in the monomeric or intercalated dimer
conformation (15, 61, 69, 103, 119). While PilZ domain-containing proteins have been
implicated in the regulation of many cellular processes, the best characterized have
been shown to regulate motility.
PilZ protein-mediated regulation of motility can act through methods such as
expression of motility genes or protein-protein interactions. An example of PilZ proteinregulated gene expression is Klebsiella pneumoniae’s MrkH (143). This transcription
factor binds the promotor of a type III fimbriae gene cluster to facilitate biofilm formation
in the presence of c-di-GMP (143). More commonly, however, PilZ proteins have been
shown to interact with other proteins to alter function. The S.ernterica serovar
Typhimurium PilZ protein, YcgR, is the most thoroughly described c-di-GMP binding
protein (115). It interacts with c-di-GMP to associate with the flagellar motor complex
and inhibit motility (94, 115). PilZ domain proteins are an important part of a bacterium’s
c-di-GMP regulatory network. The fact that almost every genome with a diguanylate

22

cyclase, including both B. burgdorferi and B. hermsii, also contains at least one PilZ
domain protein lends evidence to that fact (109).

C-di-GMP signaling in the Borrelia
GGDEF, EAL, HD-GYP, and PilZ domain containing proteins have been found in
the genomes of most spirochete species, indicating the presence of c-di-GMP signaling
systems (109). However, the surface of c-di-GMP functionality within the Spirochaete
phylum has barely been scratched. B. burgdorferi and B. hermsii are particularly unique
in that they each harbor only one diguanylate cyclase and two phosphodiesterases.
Other species, such as P. aeruginosa have as many as 41 c-di-GMP metabolizing
proteins (109). The simplicity and genetic malleability of these bacteria make them
appealing systems in which to study c-di-GMP signaling.
The B. burgdorferi c-di-GMP network is slowly being unraveled. However, the B.
hermsii system has largely been left untouched. A sequence comparison of the B.
burgdorferi B31 and the B. hermsii DAH c-di-GMP-associated proteins reveals the high
degree of homology between these two systems and can be found in Figure 1-8. The
sequence identities of these proteins range from 65 to 76% and the sequence
similarities from 82 to 89%. The BB0419 and BH0419 are the sole diguanylate cyclases
in the respective species (Rrp1, 71, 107, 133). BB0363 and BH0363 refer to the EAL
domain containing phosphodiesterases (PdeA, 107, 132). BB0374 and BH0374 are the
HD-GYP phosphodiesterases (PdeB, 107, 131). BB0733 is the only known PilZ domain
containing protein of B. burgdorferi (PlzA) and BH0733 is the B. hermsii counterpart
(PlzC, 55, 98). Deletion mutants have been generated in each of the B. burgdorferi
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Figure 1-8. Sequence homology between the B. burgdorferi and B. hermsii c-di-GMP
metabolizing proteins. Each sequence alignment was generated in ClustalW. The
asterisk (*) labels identical residues between the B. burgdorferi and B. hermsii species. The
colon (:) labels residues with charge similarity. The period (.) labels residues with structural
similarity. The BB0419 and BH0419 had 76% identity and 89% similarity. The GGDEF is
highlighted. BB0363 and BH0363 had 69% identity and 84% similarity. The EAL domain is
highlighted. BB0374 and BH0374 had 65% identity and 84% similarity. The HD-GYP
domain is highlighted. BB0733 and BH0733 had 69% identity and 82% similarity. The PilZ
domain motifs are highlighted.
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genes listed above and their phenotypes described (55, 71, 98, 107, 131, 132, 133). A
schematic of the B. burgdorferi c-di-GMP binding system can be found in Figure 1-9.
Interference in the c-di-GMP signaling system of the Borrelia results in multiple
phenotypes. Deletion of the sole diguanylate cyclase gene, rrp1, resulted in an inability
to colonize ticks (62, 71, 133). A deletion mutant of hpk1 had a very similar phenotype
because the diguanylate cyclase activity of Rrp1 is dependent on phosphorylation by
Hpk1 (32, 62, 116). Alternatively, deletion of one of the phosphodiesterase genes
(pdeA) abolished mouse infectivity, but retained tick colonization comparable to wildtype (132). However, deletion of the other phosphodiesterase (pdeB) resulted in normal
murine infectivity and reduced, but not abolished tick survival (131). Lastly, a deletion of
the only c-di-GMP binding molecule found in B. burgdorferi, plzA, led to reduced
invasion of both the mouse and tick host (98). Most of these mutants also had
alterations in motility and chemotaxis (71, 98, 131, 132, 133). The only consistent
phenotype in all mutants was an inability to transfer between the mammalian host and
tick vector to complete the enzootic cycle, which is paramount for the perpetuation of B.
burgdorferi in the environment.

Research objectives
PlzA is the only confirmed c-di-GMP binding molecule produced by B. burgdorferi
(55). As such, it is the only possible known c-di-GMP effector. Therefore,
characterization of PlzA activity and its interaction with c-di-GMP could elucidate the
molecular mechanisms of c-di-GMP regulation in B. burgdorferi.
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Cytoplasmic Membrane

Hpk1
PdeA

Rrp1

PdeB
PlzA

Figure 1-9. Schematic of the c-di-GMP network of B. burgdorferi. The B. burgdorferi
c-di-GMP network has been characterized as to enzymatic activity if not downstream
functionality. Hpk1 is embedded in the cytoplasmic membrane and theoretically detects
an external stimuli to induce autophosphorylation of histidine residues. This, in turn,
activates the diguanylate cyclase Rrp1 to synthesize c-di-GMP from two GTP
molecules. Degredation of c-di-GMP is carried out by PdeA through linearization of the
secondary messenger into the pGpG form or by PdeB which breaks it down into two
GMP molecules. The last B. burgdorferi c-di-GMP interacting protein is PlzA, which
contains a functional PilZ domain that confers c-di-GMP binding.
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Due to its sequence homology to PlzA, the study of the B. hermsii PilZ domain
protein, PlzC, would be very appealing as one of the first steps in delineating the c-diGMP regulatory network of the TBRF spirochete. While nothing has been published on
c-di-GMP signaling in the relapsing fever bacterium, preliminary data from our lab
implies that c-di-GMP signaling has an effect on the motility, chemotaxis, and disease of
B. hermsii (54). Unfortunately, altered phenotypes in enzootic cycle progression cannot
be assessed at this time since there are no uninfected O. hermsi ticks commercially
available.
Through biochemical and biophysical methods such as amino acid substitution,
fluorescence resonance energy transfer, isothermal titration calorimetry, and size
exclusion chromatography, our lab has shed light on the c-di-GMP interaction with the
only PilZ domain containing proteins of B. burgdorferi and B. hermsii, PlzA and PlzC
respectively.
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Chapter 2: Materials and Methods

Borrelia strains and cultivation
B. burgdorferi B31-5A4 cells were cultivated in Barbour-Stoenner-Kelly (BSK-H)
media supplemented with 6% rabbit serum (10). B. hermsii DAH cells were cultivated in
BSK-H media supplemented with 12% rabbit serum. All strains were maintained under
humidified conditions with 5% CO2 and at 25, 33, or 37oC. These isolates are listed in
Table 2-1.

Plasmid construction
Strains and plasmids used in this study are listed in Table 2-1. All fluorescent
resonance energy transfer (FRET) expression plasmids were derived from pFRET12AA
plasmid (89). The construct constitutes a flanking fluorescence resonance energy
transfer (FRET) pair (YFP and CFP) on either side of a multiple cloning site and
encodes twelve amino acids. The mYPet (YFP) and mCyPet (CFP) genes contain
mutations that prevent oligomerization that could interfere with signal. A positive control
FRET construct, MC0118 (kindly provided by Dr. Samuel Miller) contains the
Salmonella enterica serovar Typhimurium gene encoding the PilZ domain protein YcgR
and exhibits a characterized conformational change upon binding of c-di-GMP using
FRET [Christen, 2010 #2452]. A SpeI site was introduced at the 5' end and a KpnI site
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Table 2-1. Strains and plasmids used in this study.
Strain or Plasmid

Description

Source

E. coli NovaBlue
E. coli BL21 (DE3)
B. hermsii DAH
B. burgdorferi B31
pFRET12aa

pET15b::mYPet_12AA_mCyPet

(89)

MC0118

pET15b::mYPet_ycgR_mCyPet

(39)

pFRETplzC

pET15b::mYPet_plzC_mCyPet

this work

pFRETplzA

pET15b::mYPet_plzA_mCyPet

this work

pFRETplzAR145D

pET15b::mYPet_plzAR145D_mCyPet

this work

pFRETplzAR145K

pET15b::mYPet_plzAR145K_mCyPet

this work
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at the 3' end of all PCR products. plzA (BB0733) was amplified from genomic DNA of
the B. burgdorferi strain B31. plzC (BH0733) was amplified from the DAH strain of B.
hermsii.

Using splice overlap exchange techniques, the plzA arginine residue at

position 145 was substituted with an aspartic acid (AGA to GAT) and a lysine (AGA to
AAA). All primers used in this study can be found in Table 2-2.

Upon sequence

confirmation of each construct, the plasmids were transformed into BL21 (DE3) cells.
Schematics of the pFRETplzA plasmid and the pFRETplzC plasmid can be found in
Figure 2-1.
For the purpose of His-tagging PlzA, PlzAR145D, PlzAR145K, and PlzC, plzA
was PCR amplified from B31 gDNA and plzC from DAH gDNA. plzAR145D and
plzAR145K were amplified from their respective FRET constructs using the plzA specific
primers. PCR products were then inserted into pET45b(+, Novagen) using restriction
sites indicated by the primer name in Table 2-2. Plasmids were sequence verified and
transformed into BL21 (DE3) cells for protein expression.

Protein expression and purification.
All proteins in the study were expressed in Lysogeny Broth supplemented with
100 µg/mL ampicillin. Cultures of the transformed BL21 (DE3) cells were grown to log
phase at 37C then chilled on ice for 15 min. Protein expression was induced with
isopropyl ß-D-1-thiogalactopyranoside (IPTG). FRET proteins were induced with IPTG
at a 20 µM concentration for 24 hours at 18C. His-tagged proteins were induced with
IPTG at a concentration of 200 µM for 18 hours at room temperature.

Cells were

recovered by centrifugation then lysed with lysozyme (1 mg/mL) and sonication.
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Table 2-2. Oligonucleotides used in this study.
Primer name

Primer sequence

PlzA Spe I 5' F

ATAGTGACTAGTATGCTTTTATCTAGAAAAATAAGAGATTATGGGGCTAAGTATAGG

PlzA Kpn I 3' R

ATAGTGGGTACCATTGAAATAATCATGGATCAACATAGTATACTCAAGTGGTATTTTATC

PlzA R145D SOE 5' F

GGGCAAAATCAGGATATTCATGAGAGGATTATTATCGATAAAGATTCTATTAGAAAGC

PlzA R145D SOE 3' R

CCTCTCATGAATATCCTGATTTTGCCCAAGCTTTAAATCAAGAAGC

PlzA R145K SOE 5' F

GGGCAAAATCAGAAAATTCATGAGAGGATTATTATCGATAAAGATTCTATTAGAAAGC

PlzA R145K SOE 3' R

CCTCTCATGAATTTTCTGATTTTGCCCAAGCTTTAAATCAAGAAGC

PlzC Spe I 5' F

ATAGTGACTAGTATGTTTTTGTCTCGAAAAATAAAAGATTATGAAGTTAAGTATAAGG

PlzC Kpn I 3' R

ATAGTGGGTACCATTAAAATAATCATGGATTAACATAGTATAAGCAAGGGGAATC

PlzA Age I 5' F

ATAGTCACCGGTCTTTTATCTAGAAAAATAAGAGATTATGG

PlzA Xho I 3' R

CTATCACTCGAGTTAATTGAAATAATCATGGATCAACATAGTATACTC

PlzC Xho I 5' F

TATCACCTCGAGATGTTTTTGTCTCGAAAAATAAAAGATTATGAAGTTAAGTATAAGG

PlzC Xho I 3' R

TATCACTTAATTAAAATAATCATGGATTAACATAGTATAAGCAAGGGGAATC
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Figure 2-1. Schematic of FRET constructs and recombinant proteins. Panel A is a
depiction of the FRET protein expression plasmids used in this study. The left was used
for expression of YFP-PlzA-CFP, YFP-PlzAR145D-CFP, and YFP-PlzAR145K-CFP. The right
was used for expression of YFP-PlzC-CFP. Panel B is a depiction of all of the FRET
proteins used in this study, including the YFP-CFP negative control and the YFP-YcgRCFP positive control.
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Soluble proteins were isolated by high speed centrifugation and purified using Ni-NTA
affinity chromatography with His-trap columns (GE Healthcare) on an AKTA purification
system (GE Healthcare).

The FRET proteins were dialyzed into PBS and the His-

tagged proteins into a buffer containing 150 mM NaCl and 10 mM Tris (pH 8.0) using
Spectra/Por dialysis membranes (Spectrum Laboratories).

Proteins were quantified

using a bicinchoninic acid protein assay kit (Pierce) or 280 nm wavelength absorption,
then visualized via Coomasie-stained sodium dodecyl sulfate polyacrylamide gel
electrophoresis (BioRad) to assess purity.

FRET analysis
Assays were performed using a PHERAstar FS microplate reader (BMG) with a
YPET CYPET 425 480 530 filter. Excitation was induced with a light wavelength of 425
nm and fluorescence intensity was detected at 480 nm (CFP emission) and 530 nm
(YFP emission).

Fluorescence intensity was measured every 0.2 seconds at each

wavelength over 30 seconds. Recombinant FRET proteins (500 nM) were assayed in
triplicate in low volume 384-well black plates (ProxiPlate). 5 µL of c-di-GMP (Biolog)
was injected at the 5 second time point for a final concentration of 25 µM in 25 µL.

Size exclusion chromatography
His-tagged PlzA and PlzC (40 µM) were incubated with and without c-di-GMP (40
µM) in 550 µL of a buffer containing 150 mM NaCl and 10 mM Tris (pH 8.0) on ice for 1
hour. A control of c-di-GMP alone was also incubated. 500 µL of each reaction was
separated on a Superdex-75 column (GE Healthcare) using an AKTA purification
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system (GE Healthcare) and elution monitored at 280 nm. 250 µL fractions were
collected for later analyses.

Reverse phase chromatography
Three of the protein and c-di-GMP elution fractions were consolidated into 750 µL
samples. These samples were boiled for 10 min to denature the protein, then
centrifuged at 14,000 rpm for 15 min to remove the precipitated protein. The aqueous
portions were filtered using Amicon Ultracel filters with a molecular weight cut off of 3
kDa (Millipore). 500 µL of each sample was injected into the 15 x 4.6 cm Supelcosil LC18-T column (Supelco) using an AKTA purification system (GE healthcare). The reverse
phase gradient program used a buffer on line A containing 100 mM KH2PO4 and 4 mM
tetrabutyl ammonium hydrogen sulfate (pH 5.9) and the buffer on line B was 75% buffer
A and 25% methanol. The step gradient ran at a flow rate of 0.5 mL min -1 for 18 mL. The
program is as follows with the time point and percentage of buffer B: 0 min, 0%; 7.0 min,
30%; 14.0 min, 60%; 19.6 min, 100%; 30.8 min, 50%; and 32.2 min, 0%. Absorbance
was measured at the 254 nm wavelength for the detection of nucleic acids.

Isothermal titration calorimetry
ITC was performed using a VP-ITC microcalorimeter (MicroCal) at 25C. Histagged proteins and c-di-GMP were suspended in a buffer containing 150 mM NaCl and
10 mM Tris-HCl (pH 8.0). PlzA and the two substitution mutant proteins were assayed
at a concentration of 50 µM in the cell with 1 mM c-di-GMP titrating in the cell from the
syringe. 20 µM of PlzC was assayed in the cell with 0.2 mM c-di-GMP in the syringe.
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For all reactions, the initial c-di-GMP injection was a 0.5 µL volume over a duration of 1
s with a spacing of 120 s. 23 more injections of 1.5 µL followed for a 3 s duration and
120 s spacing. Data was analyzed using Origin software assuming a single binding site
(MicroCal).
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Chapter 3: Results

Recombinant protein purity
FRET recombinant proteins (YFP-YcgR-CFP, YFP-PlzC-CFP, YFP-PlzA-CFP,
and subsequent PlzA mutants) were shown at the expected size of ~85 kDa while the
negative control (YFP-CFP) migrated at a molecular weight of 58 kDa (Figure 3-1a).
His-tagged PlzA, PlzAR145D, and PlzAR145K migrated to the expected molecular weight of
30 kDa and PlzC, to 35 kDa (Figure 3-1b).

PlzA and PlzC undergo a FRET-detectable conformational change when c-di-GMP
binds
FRET is a technique that utilizes fluorophores that share the same wavelength
range of emission by a donor and excitation by an acceptor. Therefore, the relative
proximity of a donor to an acceptor molecule can be measured based on the amount of
transference. If a FRET pair flanks a ligand receptor that exhibits a conformational
change upon ligand binding, the changes in the distance and/or orientation of the two
fluorophores due to ligand binding can be detected through fluctuations in the emission
ratio. The specifics of this technique can be seen in Figure 3-2.
In vitro kinetics of the YFP-PlzA-CFP and YFP-PlzC-CFP proteins displayed a
change in the emission ratio (480 nm/530 nm) upon addition of c-di-GMP that is
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Figure 3-1. SDS-PAGE of recombinant proteins purified in this study. 1 µg of purified
recombinant protein was run on a 15% Tris-HCl polyacrylamide gel. The gel was stained
with Coomasie Brilliant Blue. Panel A consists of the His-tagged FRET recombinant
proteins. Panel B consists of the His-tagged recombinant proteins. All proteins migrated to
the expected molecular weight, shown by the ladder and arrows on the left.
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425 nm

425 nm
530 nm

530 nm

480 nm

480 nm

Figure 3-2. Fluorescence resonance energy transfer for conformational change
detection. CFP is excited by a laser beam with a wavelength of 425 nm , which can in turn
excite YFP with a 480 nm emission, which results in a secondary emission at 530 nm. The
efficiency of this energy transfer is dependent on the distance between these two
fluorophores. Therefore, the relative proximity/orientation of the YFP and CFP can be
measured based on the energy transfer between them. By introducing a spacer protein
between the FRET pair, a structural rearrangement due to ligand binding can be detected
by a change in the emission ratio of YFP and CFP.
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depicted in Figure 3-3. This is indicative of a c-di-GMP-induced conformational change
in PlzA and PlzC. YFP-YcgR-CFP displayed a similar decrease in FRET efficiency after
c-di-GMP injection that is comparable to previous studies (39). In vitro kinetics of the
YFP-CFP protein confirmed that the fluorophores do not independently undergo a c-diGMP-induced conformation change in since there is no change in the emission ratio
when c-di-GMP is injected.

PlzAR145D loses conformational change while PlzAR145K behaves similarly to PlzA
The YFP-PlzAR145D-CFP protein exhibited no change in the emission ratio after cdi-GMP injection. Therefore, there was a loss of c-di-GMP-induced conformational
change by PlzA when the arginine at position 145 was mutated into an aspartic acid,
shown in Figure 3-4. However, the YFP-PlzAR145K-CFP protein did have a change in
the emission ratio, therefore, a structural rearrangement was detected when binding cdi-GMP and mutating Arg145 into a lysine did not disrupt the c-di-GMP-induced
conformational change by PlzA.

PlzA and PlzC exist as monomers both bound and unbound to c-di-GMP
Using size exclusion chromatography, our lab analyzed the c-di-GMP-bound and
unbound state of PlzA and PlzC for oligomerization. PlzA and PlzC alone eluted off of
the column at the monomeric molecular weight. Additionally, after being incubated with
c-di-GMP, each protein eluted at a molecular weight comparable to the unbound
protein, indicating that the monomeric state was maintained (Figure 3-5).
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Figure 3-3. C-di-GMP induced conformational change by PlzA and PlzC detectable
by FRET. Excitation of FRET proteins was induced with a 425 nm laser beam and
fluorescence intensity was detected at 480 nm (donor emission) and 530 nm (acceptor
emission). Fluorescence intensity was measured at each emission wavelength for 30 s.
The raw fluorescence intensity measurements over time are displayed in the bottom graph
of each panel. C-di-GMP was injected into the wells at the 5 s time point . Therefore, a
change in the emission ratio at 5 s is indicative of a c-di-GMP-induced conformational
change. The emission ratio of each protein over time can be found in the top graph of each
panel. YFP-CFP acted as a negative control with no change in the emission ratio. YFPYcgR-CFP acted as a positive control, with a change in the emission ratio at the 5 s time
point. Both YFP-PlzA-CFP and YFP-PlzC-CFP exhibited a change in the emission ratio
upon addition of c-di-GMP.
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Figure 3-4. FRET analyses of PlzA with a drastic and conservative substitution
mutation of arginine 145. PlzA substitution mutants of position 145 were introduced
into the FRET construct to characterize the PlzA c-di-GMP binding domain. FRET
assays were conducted similarly to Figure 3-3. The YFP-PlzA-CFP graphs on the left
are for comparison. The R145D substitution mutant protein resulted in an abolishment
of the change in the emission ratio upon c-di-GMP binding. However, the R145K
substitution mutant retained the structural rearrangement exhibited by the YFP-PlzACFP protein.
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Figure 3-5. PlzA and PlzC exist as monomers in both the apo and holo form. Size
exclusion chromatography results of proteins with and without c-di-GMP on an Superdex75 column, detection was with 280 nm absorbance. Specific fractions were collected and
run on a reverse phase column. Those fractions are denoted by the brackets and the
reverse phase results of those fractions indicated by the arrow. C-di-GMP detection was
with 254 nm absorbance . The PlzA and PlzC alone fractions (panel A and C) saw no
detection of c-di-GMP. They each eluted at the monomeric molecular weight based on a
standard curve. Incubation of PlzA and PlzC with an equivalent concentration of c-di-GMP
was carried out, then run on a gel filtration column. Again, PlzA and PlzC eluted at the
monomer molecular weight (panel B and D). The protein and c-di-GMP elution fractions
were then injected onto a reverse phase column to detect for c-di-GMP and confirm that the
proteins were bound to c-di-GMP. To verify the c-di-GMP retention volume, an equal
concentration and volume of c-di-GMP was run on the gel filtration column and the elution
fraction run on the reverse phase column. The c-di-GMP retention volume off of the gel
filtration column and the elution volume off of the reverse phase column were consistent
with the PlzA:c-di-GMP and PlzC:c-di-GMP runs (panel E).
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To confirm that c-di-GMP was present or absent in the appropriate eluates,
elution fractions from the size exclusion chromatography were loaded onto a reverse
phase column to detect the di-nucleotide. A peak at the 18 mL retention volume in the
protein and c-di-GMP elution fractions of both the PlzA-c-di-GMP and PlzC-c-di-GMP
run confirmed that c-di-GMP is bound by these proteins. The absence of this peak in the
protein fraction of the PlzA and PlzC alone runs served as negative controls.

Thermodynamic characterization of the PlzA:c-di-GMP and PlzC:c-di-GMP
interactions
ITC methods were performed to measure the energy usage in maintaining a set
temperature as the c-di-GMP ligand was titrated into a solution containing the Borrelia
c-di-GMP receptors. In this way, the amount of heat produced or absorbed by the
reaction could be detected and a sigmoidal titration curve obtained. From this curve, the
stoichiometry and affinity of the receptor for the ligand could be calculated. In addition,
by detecting the energy necessary to return the sample temperature to 25oC. the net
enthalpy change can be measured from which the net change in entropy can be
calculated using the Gibbs free energy equation. Thus, the c-di-GMP interactions with
recombinant PlzA and PlzC were characterized. Raw kinetic measurements of power
compensation and titration curves can be found in Figure 3-6. Based on the data, the
dissociation constant of PlzA:c-di-GMP was calculated to be 6.25±1.10 µM and PlzC:cdi-GMP was 5.92±0.963 µM. The binding stoichiometries of both associations were
~1:1. These interactions were exothermic and enthalpy-driven, exhibiting high net
changes in enthalpy and low net changes in entropy. Drastic net entropic changes
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PlzA:c-di-GMP

PlzAR145D:c-di-GMP

A)

B)

PlzAR145K:c-di-GMP

PlzC:c-di-GMP

D)

C)

Figure 3-6. PlzA and PlzC bind c-di-GMP with moderate affinity. Isothermal titration
calorimetry was conducted to characterize the interaction of PlzA, PlzAR145D, PlzAR145K,
and PlzC with c-di-GMP at 25°C. The top panels depict the raw isotherm titration
calorimetry data. The bottom panels show the binding isotherm data with calculated,
dilution-corrected heat release for each reaction with a fit curve using a single site
interaction model. Thermodynamic profiles of these reactions can be found in Table 3-1.
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would suggest hydrophobic interactions because of a reduced organization of the water
molecules that interact with the protein surface. However, the PlzA:c-di-GMP and
PlzC:c-di-GMP ITC data indicate that the heat release in these reactions is due to
hydrogen bond formation, not hydrophobic interactions. The complete thermodynamic
profile of PlzA:c-di-GMP and PlzC:c-di-GMP can be found in Table 3-1.
For the purpose of the PlzA and PlzC PilZ domain characterization, our lab
mutated Arg145 into an aspartic acid and lysine residue. The PlzAR145D and PlzAR145K
interactions with c-di-GMP were measured under the same conditions as PlzA and
supported the FRET analyses. PlzAR145D exhibited no significant binding events with cdi-GMP and PlzAR145K binding was comparable to PlzA.
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Table 3-1. Thermodynamic profiles of PlzA, PlzC, PlzAR145D, and PlzAR145K.
Syringe:

c-di-GMP

c-di-GMP

c-di-GMP

Cell:

PlzA

PlzAR145K

PlzC

Kd (µM)

6.25±1.10

1.18±0.460

5.92±0.963

0.91±0.032

0.693±0.026

1.12±0.034

-13.7±0.673
-22.1

-11.6±0.599
-9.95

-13.7±0.749
-22.0

N (syringe/cell)
-1

H (kcal mol )
S (cal mol-1 K-1)
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Chapter 4: Discussion

C-di-GMP is a ubiquitous signaling molecule utilized by many bacterial species in
the regulation of cellular processes (109). Since its discovery 25 years ago, this dinucleotide has been implicated in the modulation of many factors contributing to host
invasion (109). However, it is not c-di-GMP itself that carries out these effector
functions, but the receptors to which it binds (109).

Therefore, the discovery and

characterization of these c-di-GMP effectors is highly desirable.
Many c-di-GMP receptors contain other recognizable domains, such as the helixturn-helix of a DNA binding domain or a membrane fusion domain for ABC transporters
(81, 109, 143). While PlzA and PlzC each have C-terminal PilZ domains, their
sequences contain no other clues as to their purpose within the cell since they harbor
no significant sequence homology to known protein domains. Therefore, insights into
their potential function and activity must be delineated by examining c-di-GMP effects
within the Borrelia.
Multiple groups have worked to divulge c-di-GMP functionality in the Lyme
spirochete. Rogers et al. (107) was the first to generate an rrp1 deletion mutant (Δrrp1)
and eliminate the source of c-di-GMP synthesis. Through transcriptome analysis of
Δrrp1, it was found that in the absence of the diguanylate cyclase, 140 genes had
altered expression, which correlates with ~10% of the genome. Several of these genes
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are involved in motility, chemotaxis, and metabolism, implying that c-di-GMP may
function to regulate these processes.
One of the many interesting genes within the Rrp1 regulon is rpoS, one of the
alternate sigma factors of B. burgdorferi. Specifically, this transcriptional modulation
appears to be through the oxidative stress response regulator, BosR (133). Decreased
protein expression of both BosR and RpoS occurred in Δrrp1 (133). How BosR is
activated to promote RpoS transcription is unknown, but appears to be through a c-diGMP effector.
Many other studies have found that that both Rrp1 and Hpk1 are upregulated
during tick feeding (55, 87, 107). This implies that the Rrp1-Hpk1 system may be
important in the expression of genes significant for spirochete survival in the tick and
was confirmed experimentally with tick infection studies (62, 71). Thus, it became
readily apparent that c-di-GMP has a part to play in B. burgdorferi survival within the
tick.
One pathway by which c-di-GMP appears to affect tick invasion is through
activation of the glycerol metabolic pathway (62). An operon of glycerol transport and
metabolism genes (glp) was reported to be a part of the Rrp1 regulon through multiple
microarray studies (62, 107). Since glucose is an ample source of nutrients in the
mammalian host, Δrrp1 would be unaffected during murine infection. However, glycerol
is likely an important carbon source for the spirochete in the tick vector. A deletion
mutant was generated in the glp operon to assess if this pathway is the sole cause of
the altered Δrrp1 phenotype (62). The glp mutant was capable of survival within the tick,
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albeit at a reduced level (62). This indicates that there is at least one other c-di-GMPregulated factor that contributes to B. burgdorferi proliferation in the tick.
While the absence of c-di-GMP appears to only significantly affect colonization of
the tick vector, uncontrolled production has a negative effect on both tick and
mammalian invasion by B. burgdorferi (71, 131, 132). The pdeA deletion mutant had
increased intracellular c-di-GMP accumulation and was unable to infect mice even at
very high bacterial loads (132). Additionally, an Rrp1 overexpression strain was unable
to infect either the murine or arthropod host (71). This phenotype within the Borrelia is
consistent with the rest of the bacterial world where high levels of c-di-GMP correlate
with decreased infectivity (109).
Since c-di-GMP signaling in the Borrelia appears to be very important in host
invasion and enzootic cycle progression, the discovery of the responsible effector
molecule(s) is vital to delineating the mechanism of c-di-GMP activity. PlzA and PlzC
are the only confirmed c-di-GMP binding molecules within the Borrelia. Like rrp1, plzA
transcript levels are upregulated during tick feeding (55). This indicates that factors of
the bloodmeal induce the transcription of plzA even though it is not within the Rrp1
regulon (107). Multiple groups have generated plzA mutant strains and each had
decreased infectivity in mice by needle inoculation as well as decreased colonization of
the tick by immersion (70, 98). Despite invasion of both the vector and mammalian host,
albeit mitigated, natural transmission of the spirochete from one host to the other did not
occur (98). Therefore, a plzA mutant is incapable of completing the enzootic cycle,
which correlates with the phenotypes of other B. burgdorferi strains with mutated c-diGMP-associated genes. In addition to a plzA mutant, Pitzer et al. created a plzA
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deletion in the pdeA mutant background (98). This strain had detectably higher
intracellular c-di-GMP levels, but the phenotype of the pdeA and pdeA-plzA deletion
mutants were identical. Therefore, the non-pathogenic phenotype of the pdeA mutant is
not because of altered PlzA activity due to bolstered c-di-GMP levels in the spirochete.
Along with mitigated infectivity, the plzA deletion mutant displayed decreased
motility speed (70). This phenotype could be accounted for through altered motility gene
expression or protein-protein interactions with the flagellar motor. Changes in the
transcription levels of fliG1, cheY3, and fliI by the plzA mutant implicate the former, but
does not exclude the latter (70). Unlike most other bacterial species, the B. burgdorferi
genome encodes two motor switch FliG proteins (FliG1 and FliG2, 52). FliG2 appears to
function as a traditional motor switch protein, localizing to each periplasmic flagellar
bundle (74). Conversely, FliG1 localizes to one of the poles and, interestingly, a fliG1
deletion mutant has only one functional flagellar bundle (74). Analysis of the fliG1
mutant in viscous media revealed that each bundle comprises normal flagellar
filaments, but only one managed to gyrate, which resulted in severely decreased
translational motion (74). This presented a unique opportunity to test the necessity of
motility in B. burgdorferi infectivity without interfering with the architecture that the
flagella provide (74). Murine infection studies supported that a fliG1 mutant is noninfectious, reaffirming the significance of motility in spirochetal pathogenicity (25, 74).
While both motors of the plzA mutant do manage to gyrate in viscous media, the
translational speed and flexation per second were severely reduced (70). It is tempting
to speculate that this phenotype is because of altered FliG1 activity due to a lack of
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PlzA regulation. However, more studies must be conducted on the functionality and
potential interaction of PlzA with FliG1.
In an effort to shed light on the activity and biochemistry of PlzA and the B.
hermsii homologue, PlzC, this study sought to explore their interaction with c-di-GMP.
Often, ligand binding induces a conformational change in the receptor and results in an
alteration in function. A method of detecting this is FRET where the protein in question
is flanked by a FRET pair. Changes in the relative distance or orientation of the protein
termini upon ligand binding can be detected by measuring the emission ratio of the
FRET pair.
Through FRET analyses, this study divulged that the only known c-di-GMP
receptors encoded by the Lyme spirochete, B. burgdorferi, and the TBRF spirochete, B.
hermsii, exhibit a structural rearrangement when binding c-di-GMP likely significant to
downstream functions. Both of the PilZ proteins had a decrease in FRET efficiency
upon addition of c-di-GMP; this could be due to an increase in the distance between the
amino and carboxyl termini of the protein or simply due to a change in the orientation.
However, c-di-GMP-induced oligomerization or monomerization of the FRET proteins
could also result in interference and affect the analysis. Therefore, the potential for PlzA
and PlzC multimerization had to be assessed.
The Pseudomonas putida PilZ domain protein PP4397 has been shown to
transition from a dimer to a monomer based on c-di-GMP binding (119). When bound by
PP4397, c-di-GMP occludes the dimeric interface, preventing dimerization (69).
Therefore, a change in state induced by c-di-GMP binding does occur in other PilZ
domain proteins. However, size exclusion chromatography of PlzA and PlzC bound and
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unbound to c-di-GMP upheld that these proteins exist as monomers in the apo and holo
state. Therefore, the change in FRET efficiency exhibited by PlzA and PlzC is due to
intramolecular rearrangements upon ligand binding and not intermolecular interactions.
Cyclic di-GMP is a freely diffusible molecule and bacteria lack an apparent
means of physical sequestration in the form of membrane-bound organelles. Therefore,
varying receptor affinities, intracellular localization, and differential expression levels
have a key role to play in where and when c-di-GMP affects cell processes (65). A study
was conducted in S. enterica serovar Typhimurium in which the disparate affinities of
the only two PilZ domain proteins were found to be significant in governing two different
cellular processes based on intracellular c-di-GMP concentrations (101). YcgR has
been implicated in c-di-GMP-induced negative regulation of flagellar rotation through
protein-protein interactions. This is in order to initiate the transition from motility into
sessility. YcgR is also a c-di-GMP receptor with one of the highest known PilZ domain
affinity for c-di-GMP (~190 nM, 37, 101). Alternately, the only other PilZ domain protein,
BcsA, has a comparatively modest affinity of 8.2 µM. Upon c-di-GMP binding, BcsA
positively regulates cellulose production, a function that facilitates biofilm formation.
Therefore, it was hypothesized by Putz et al. that there is a c-di-GMP concentration
threshold for each of these proteins that must be surpassed before the c-di-GMPdependent function can be performed (101). In the case of this study in Salmonella
Typhimurium, the YcgR threshold is lower so that as c-di-GMP is synthesized motility is
depressed before the BcsA threshold is reached and cellulose production initiated
(101).
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The binding affinities of PlzA and PlzC for c-di-GMP were calculated using
titration methods. They share a similar affinity, which is not surprising considering the
high degree of sequence homology between the two. In this study, PlzA’s affinity for cdi-GMP was calculated to be 6.25 µM and PlzC’s was 5.92 µM. Comparing these
affinities with the Salmonella PilZ proteins revealed that they are closer to the affinity of
BcsA than YcgR. However, the phenotype of a plzA mutant more closely correlates with
YcgR activity in that it affects bacterial motility. Since YcgR interacts with the motor
switch protein, FliG and FliM, it is appealing to consider that PlzA may act in a similar
manner.
The Borrelia c-di-GMP receptors, PlzA and PlzC, harbor multiple residues that
are highly conserved among PilZ domain proteins. A sequence comparison of PlzA and
PlzC to other PilZ domains can be seen in Figure 4-1. Substitution mutations and
structural determination of other PilZ domains have shown that the two arginines of the
RxxxR motif directly interact with c-di-GMP, primarily through hydrogen bond formation
and non-covalent interactions (69). Several other residues also seem to affect c-di-GMP
binding, these can include those in the DzSxxG motif or other residues more distal in
sequence from the PilZ domain (37, 56, 69, 81, 113, 115, 119). However, unlike the
RxxxR, these seem to vary a great deal.
In order to further characterize the PilZ domain of PlzA, our lab generated
recombinant proteins with substitutions of the arginine at position 145, which is the first
in PlzA’s 145RxxxR motif. The first was a conservative mutation from an arginine to a
lysine. Both of these amino acids are basic with the two highest isoelectric points of the
amino acids. Additionally, their structures are alike in that their side chains are similar in
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Figure 4-1. Sequence alignment of the Borrelia PilZ domain proteins with other
characterized PilZ domain proteins. Alignment was generated by ClustalW 2.0 and
ESPRIPT. Identical amino acids are highlighted and similar amino acids are surrounded
by a box. High conservation of the RxxxR/DzSxxG PilZ motif between all proteins,
including PlzA and PlzC is shown. VCA0042 is PlzD of V. cholera. DgrA and DgrB are
encoded by Caulobacter crescentus. PA4608 is a P. aeruginosa PilZ domain protein.
PP4397 is produced by P. putida. CesA is from G. xylinum. MrkH is encoded by
Azospirillium brasilense. YcgR is a c-di-GMP binding protein associated with motility in
Salmonella Typhimurium.
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length and end in a positively charged nitrogen-based group, although arginine
comprises a guanidinium group and lysine, an amino group. The retention of c-di-GMP
binding and structural rearrangement capabilities must be attributed to the high degree
of similarity between these two amino acids. The second was a drastic mutation from an
arginine to an aspartic acid. The difference in the isoelectric points of these two amino
acids is the most extreme of any pair. This mutation ensured that the localized surface
charge of the 145RxxxR motif would be significantly altered. Results obtained in this
study have shown that this mutation did, indeed, not only abolish the conformational
change, but resulted in no detectable binding of c-di-GMP by PlzA. Other mutations of
this particular residue within other PilZ domain proteins from an arginine to an alanine
have also led to abolished c-di-GMP binding (100, 119). The fact that the PlzAR145K
substitution recombinant protein was still capable c-di-GMP binding and conformational
change suggests that the interaction is not necessarily primary sequence dependent.
However, the abolishment of binding in the PlzAR145D protein and retention of binding in
the PlzAR145K protein indicates that a positively charged at position 145 is very important
in the PlzA-c-di-GMP interaction.
Many PilZ domain proteins contain another arginine residue just upstream of the
RxxxR motif, making it RRxxxR. Titration studies of these proteins with c-di-GMP have
revealed that every characterized protein that harbors this additional arginine residue
binds a c-di-GMP intercalated dimer, including YcgR (37, 56, 69, 113, 115, 119).
Conversely, if the PilZ domain protein retains a residue other than an arginine at that
position, the protein binds the monomeric form of c-di-GMP, including PlzD of V. cholera
(15, 69, 81). Examination of the PlzA and PlzC sequence shows that neither encodes
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an arginine at this position. The titration analyses in this study revealed that both of
these bind c-di-GMP with an ~1:1 ratio. An interesting study mutated the residue just
upstream of the RxxxR motif to encode an arginine in PlzD of V. cholera and
investigated the binding stoichiometry of this substitution mutant protein to find that the
ratio had shifted to a 1:2 (69). Considering the conservative metabolic nature of the
Borrelia with genetic and metabolic materials, it is not surprising that these bacteria
should evolve to encode a c-di-GMP receptor that only binds one molecule of its ligand
instead of two.
While PlzA is the only known c-di-GMP receptor encoded by the Lyme
spirochete, in comparing the phenotypes of the rrp1 and plzA deletion mutants, it is
apparent that there may be other c-di-GMP effectors produced by the Lyme spirochete.
Otherwise, the two mutants would exhibit more comparable phenotypes. Another
speculation is that PlzA may have functionality independent of c-di-GMP binding.
Phenotypic characterization of a B. burgdorferi mutant encoding a non-c-di-GMP
binding PlzA, such as PlzAR145D, would be crucial in elucidating the role of c-di-GMP
binding by PlzA in vivo.
Most research efforts in delineating the c-di-GMP functionality in spirochetal
regulatory networks has been concentrated in B. burgdorferi and, more recently, B.
hermsii. However, it is significant to note that there appear to be c-di-GMP networks in
all of the Borrelia with sequenced genomes (109). Analyses of the B. bissettii, B. afzelii,
B. valaisiana, B. garinii, B. spielmanii, B. turicatae, B. duttoni, B. recurrentis, and B.
crocidurae genomes have revealed that these Lyme and relapsing fever spirochetes
harbor genes that share a great deal of homology with the B. burgdorferi and B. hermsii
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c-di-GMP systems, including PlzA and PlzC. Additionally, the activity of a PilZ domain
protein encoded by another pathogenic spirochete, Treponema denticola, was
investigated very recently (19). The results of this study revealed that a deletion mutant
of the c-di-GMP receptor TDE0214 exhibited altered motility and reduced biofilm
formation (19). Research in c-di-GMP signaling by the spirochete is expanding to further
delineate its potential roles in biochemical processes and pathogenesis.
In summary, the c-di-GMP regulatory networks of B. burgdorferi and B. hermsii
have significant involvement in many processes, including motility, metabolism, and
survival. While the modulation of c-di-GMP levels within the cell through diguanylate
cyclases and phosphodiesterases is very important for governing downstream effectors,
c-di-GMP receptors are what perform the mediated functions of this signaling molecule.
As the only known c-di-GMP binding factors within the Borrelia, the interactions of PlzA
and PlzC with c-di-GMP are vital in determining the mechanism of c-di-GMP-mediated
host invasion by the Lyme and relapsing fever spirochetes. In other effectors, the
mechanism that c-di-GMP alters protein activity literally hinges around the loop-forming
RxxxR motif into which di-nucleotide nestles. In this study, the structural rearrangement,
monomeric state, binding stoichiometry, and ligand affinity of PlzA and PlzC were
determined. These properties must contribute to their function within the cell, which has
been shown to be significant in motility, infectivity, and enzootic cycle progression.
Future endeavors in characterizing the c-di-GMP regulatory networks of the
Borrelia would include detection of c-di-GMP synthesis in vivo during different stages of
the enzootic cycle. The use of a biosensor with a detectable output would be imperative.
Studies in Caulobacter crescentus have used a FRET biosensor in this manner (39).

57

Therefore, mutagenesis of the Lyme and relapsing fever spirochetes to express the
FRET proteins described in this study would further delineate how c-di-GMP functions
within these bacterial species.
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